Reaction profile

The FDA adverse-event record for eye neoplasm

Name: Eye neoplasm - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

31 FDA reports name eye neoplasm, a lower-volume reaction in the CVM extract (VeDDRA 1987). Plate stamps and neighbourhood peers follow.

#1973 of 2,481
by report volume (all reactions): 31
reports citing this reaction: 25.8%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Eye neoplasm has 31 reports now versus 31 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: −0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Eye neoplasm changes

FDA AER · VeDDRA plate

Code 1987 VOL-TRACE

VOL-TRACE · DEATH-HOT · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 31 reports
DEATH-HOT 25.8%
LOWER-Q #1973/2481
PHOTO-FINISH ABNORMAL TEST RESULT,…
SPECIES-DOG Dog · 25
DRUG-LEAD Milbemycin Oxime… · 8
DESK-WIDE 20 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: ABNORMAL TEST RESULT, THYROID NOS (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Eye neoplasm

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Eye neoplasm

Eye neoplasm: high death-coded share in the FDA AER plate

Signature read: 31 reports place Eye neoplasm in the lower third of FDA AER volume (#1973 of 2,481). Report volume is lower-third scale: 31 named reports in the openFDA extract. Death-coded share is upper-third: 8 of 31 reports (25.8% of named reports). Nearest volume peer: ABNORMAL TEST RESULT, THYROID NOS (±0 reports). Lead species Dog (25). Lead co-reported drug Milbemycin Oxime + Spinosad (8).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 25

Cat 6

Breeds Most Affected

Retriever - Labrador 5

Domestic Shorthair 2

Spaniel - Cocker American 2

Domestic Mediumhair 2

Retriever - Golden 2

Dog (unknown) 2

Chihuahua 1

Domestic Longhair 1

Doberman Pinscher 1

Boxer (German Boxer) 1

Associated Drugs

Milbemycin Oxime + Spinosad 8

Carprofen 3

Emodepside + Praziquantel 2

Oclacitinib Maleate 2

Grapiprant 2

Tramadol 2

Oclacitinib 2

Trilostane 2

Cyclosporine A 1

Phenylpropanolamine 1

Dexamethasone 1

Spinosad 1

Recombinant Human Insulin 1

Ivermectin/Pyrantel 1

Imidacloprid, Permethrin, Pyriproxyfen 1

Meloxicam 1

Pradofloxacin 1

Anesthetic 1

Allergy 1

Neomycin, Polymyxin B, And Hydrocortisone 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Eye neoplasm (#1973 of 2,481 by report volume); death-coded 25.8%. PlainBreed reaction plate · report volume stamp 31 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →